About this trial
Problem statement. Major Depressive Disorder (MDD) is a significant concern among adolescents, characterized by episodes of mood changes, cognitive symptoms, and neurovegetative dysfunction, often lasting months or even years, with a high recurrence rate. In Chile, the prevalence of adolescent MDD is estimated at 8.3%, but only a fraction receive treatment. Post-COVID-19 studies indicate a deterioration in adolescent mental health globally. Treatments for MDD include various psychotherapies, medications like Selective Serotonin Reuptake Inhibitors (SSRIs), and combined approaches, though many adolescents remain untreated or receive non-specific care. Integrated Care Pathways (ICPs), such as the CARIBOU, show promise in providing structured, multidisciplinary care. The CARIBOU model includes components like individual and group Cognitive Behavior Therapy (CBT), caregiver support, and medication algorithms within a Measurement-Based Care (MBC) framework. Pilot studies indicate the feasibility of such interventions, but further research is needed, particularly in resource- limited settings like Chile. Recent initiatives by the Chilean Ministry of Health, underscore the urgency and potential for implementing ICPs like CARIBOU in primary care to address adolescent depression effectively.
General Objective: To evaluate the acceptability, feasibility, and explore the efficacy of CARIBOU pathway in treating adolescent depression in primary care.
Specific Objectives (SO)
1. To assess the acceptability of the various components of the CARIBOU care model among adolescents, parents/caregivers, and healthcare professionals involved in the treatment of depression in primary care. 2. To assess the feasibility of implementing the different components of the CARIBOU care model for adolescents in the treatment of depression in primary care settings. For example, determine if the research team can recruit a sufficient number of participants at each participating health center within the time of the pilot cluster Randomized Controlled Trial (cRCT) study, evaluate the adherence of healthcare professionals in offering and implementing the proposed interventions, and estimate the participation level of students, parents/caregivers, and healthcare professionals in completing multiple longitudinal outcome assessments to provide sufficient data for a valid analysis. 3. To explore the efficacy of the ICP CARIBOU in reducing depressive symptoms, as measured by the short form of Mood and Feelings Questionnaire (MFQ), compared to treatment as usual (TAU) over 24 weeks. Similarly, determine if the use and implementation of CARIBOU are more effective in reducing anxiety symptoms, measured by the Generalized Anxiety Disorder 7 (GAD-7), and in improving quality of life, measured by the KIDSCREEN-27, family functioning measured by the The McMaster Family Assessment Device - General Functioning Subscale (MFAD-GF), and the overall functionality using the Columbia Impairment Scale, Youth Version (CIS-Y). Methodology. To achieve these objectives, the project will be divided into two phases. I) Formative work: a) the Translation and cultural adaptation of the program of the different components CARIBOU ICP, and b) Youth and family engagement in enhancing the design and relevance of CARIBOU interventions for adolescent depression. And II) The Intervention evaluation phase: a) a Pilot cluster Randomized Controlled Trial study to assess the acceptability and feasibility of implementation CARIBOU ICP in primary care centers and to explore the efficacy of the intervention in reducing depressive and anxiety symptoms and functional impairment and improving quality of life in primary care settings in Chile. This study will involve 72 depressed adolescents and their families randomly allocated to the CARIBOU ICP group (n=36, in two CESFAMs) and to the Treatment As Usual (TAU) (n=36, in two CESFAMs)
Expected outcomes. The research project is anticipated to deliver several key outcomes across two phases. In the formative phase, the project will successfully translate and culturally adapt the CARIBOU intervention materials for Chile. This phase will ensure the intervention and assessment tools are culturally relevant and reliable. In the evaluation phase, a pilot cRCT will assess the acceptability and feasibility of implementation of CARIBOU and will explore the intervention's efficacy, aiming to show significant reductions in depression and anxiety symptoms and improvements in overall well-being and social functioning among adolescents. The successful dissemination of findings will inform clinical practices and policymakers, potentially leading to a larger evaluation and dissemination of the CARIBOU intervention in primary care settings, thereby benefiting adolescent mental health in Chile.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adolescents aged 15 to 18 years (up to their 19th birthday).
Presenting at one of the participating primary care centers.
The primary care physician considers depressive symptoms to be a priority treatment target.
PHQ-9 score ≥5 at screening.
Disqualifiers
Severe depressive symptoms (PHQ-9 score ≥20).
Active psychotic symptoms (persistent delusions, hallucinations, or disorganized speech affecting functioning).
Bipolar disorder (type I or II).
Moderate or severe substance use disorder.
Trial design
Parallel
Treatments tested in this trial
CARIBOU Integrated Care Pathway
BehavioralAn integrated care pathway for adolescents with major depressive disorder delivered in primary care, including psychoeducation, cognitive behavioral therapy (group or individual) or Brief Psychological Intervention, caregiver support, measurement-based care, and medication management when clinically indicated.
Treatment as Usual (TAU)
BehavioralTreatment as usual consists of routine outpatient care provided in Chilean primary care centers. Participants receive standard clinical management according to local practice, which may include assessment, psychotherapy, medication management, referrals, and follow-up, without the structured CARIBOU integrated care pathway or measurement-based care framework.
Treatment groups
Trial outcomes
Primary outcomes
Acceptability of the CARIBOU Integrated Care Pathway
Acceptability of the intervention will be assessed using a questionnaire developed by the research team and qualitative interviews with adolescents, caregivers, and healthcare professionals.
Participant Satisfaction
Satisfaction with the intervention will be assessed using the adapted Client Satisfaction Questionnaire (CSQ-8). This is an 8-item instrument, validated in English and subsequently translated and validated into Spanish, that measures overall satisfaction with health services received across various populations. Responses are Likert-type, with four options each. It also includes space for comments and suggestions. This instrument will be slightly adapted to questions oriented to the context of the study. The CSQ has an internal consistency range of α = 0.83 to α = 0.93
Recruitment Feasibility
Number of participants recruited who complete the baseline assessment.
Baseline Assessment Completion
Percentage of participants completing the baseline assessment within 2 hours.
Secondary outcomes
Depressive Symptoms
Depressive symptoms measured using the Mood and Feelings Questionnaire - Short Version (MFQ). This is a self-report instrument designed to assess mood. It consists of 13 items rated on a Likert scale from 0 = "Not true" to 2 = "True." The total score ranges from 0 to 26 points. Various studies have shown that the scale is unidimensional in samples of girls and boys aged 6 to 18 years. It demonstrates high levels of internal reliability (α = 0.80 to 0.91) and validity in cohorts of children aged 8-16. The MFQ is specifically designed for children and adolescents, which may make it more suitable for this age group compared to the PHQ-9. It has strong psychometric properties, including high internal consistency and reliability, making it a robust tool for screening adolescent depression. The MFQ's ease of use and open-access nature can facilitate its implementation in various settings, including schools and primary care clinics.
Overall Functioning
Overall functioning measured using the Columbia Impairment Scale - Youth Version (CIS-Y). Is a 13-item questionnaire with versions for both parent (CIS-P) and youth (CIS-Y) ratings. It assesses family and peer relationships, engagement in hobbies, and school involvement over the past weeks using a Likert scale. The scale demonstrates high internal consistency and excellent test-retest reliability and correlates well with established measures of functioning. A score of ≥ 16 indicates significant impairment, making it suitable for inclusion due to its cost-effectiveness, quick administration, and reliable psychometric properties. In this project, we will study the psychometric properties of this instrument.
Anxiety Symptoms
Anxiety symptoms measured using the Generalized Anxiety Disorder 7-item scale (GAD-7) which is a self-report questionnaire designed to assess the severity of anxiety symptoms in adolescents and adults. It consists of seven items corresponding to the DSM-5 diagnostic criteria for generalized anxiety disorder. Respondents rate the frequency of their symptoms over the past two weeks on a scale from 0 (not at all) to 3 (nearly every day), yielding a total score ranging from 0 to 21. It has been validated among Chilean adolescents with good psychometric properties.
Health-Related Quality of Life
Health-related quality of life measured using the KIDSCREEN-27 questionnaire which is a brief questionnaire used to assess the health-related quality of life in children and adolescents aged 8 to 18. It includes 27 items that evaluate physical, emotional, mental, and social well-being, providing a comprehensive overview of a child's overall quality of life. It has been validated among Chilean adolescents with adequate psychometric properties
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: